NE 100

Drug Profile

NE 100

Latest Information Update: 14 May 2007

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Anisoles; Antidementias; Antipsychotics; Neuroprotectants; Propylamines; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 06 May 2003 Phase-II clinical trials in Schizophrenia in Japan (unspecified route)
  • 30 Oct 1998 Data have been added to the adverse events section
  • 02 Jun 1998 Phase-II clinical trials for Schizophrenia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top